^
    Back
    Association details:
    Biomarker:NPM1-ALK fusion
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Res
    Title:

    Preclinical evaluation of gilteritinib on NPM1-ALK driven Anaplastic Large Cell Lymphoma Cells

    Published date:
    01/29/2021
    Excerpt:
    ...gilteritinib mediated growth inhibitory effects on NPM1-ALK driven ALCL cells. We utilized a total of five ALCL model cell lines, including both human and murine. Gilteritinib treatment inhibits NPM1-ALK fusion kinase phosphorylation and downstream signaling, resulting in induced apoptosis...In summary, our preclinical studies explored the novel therapeutic potential of gilteritinib in the treatment of ALCL cells expressing NPM1-ALK...Our preclinical results explore the use of gilteritinib for the treatment of NPM1-ALK driven anaplastic large cell lymphoma cells...
    DOI:
    10.1158/1541-7786.MCR-20-0738
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

    Published date:
    11/06/2019
    Excerpt:
    Preclinical results suggest gilteritinib has therapeutic potential for the treatment of ALCL cells expressing NPM1-ALK and other ALK /ALK-fusion driven hematologic or solid malignancies.
    DOI:
    https://doi.org/10.1182/blood-2019-130633